Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Medicare Rx Work Begins; Merck Joins In Frist Briefing

Executive Summary

Merck is playing a key role in the preliminary Medicare legislative drafting effort in the Senate

You may also be interested in...



GSK Remains Positive On Medicare Rx, Outcome Of AWP Suit

GlaxoSmithKline continues to see only an upside from the potential creation of a Medicare prescription drug benefit, Pharmaceutical Operations President David Stout told investors in New York City Feb. 13

GSK Remains Positive On Medicare Rx, Outcome Of AWP Suit

GlaxoSmithKline continues to see only an upside from the potential creation of a Medicare prescription drug benefit, Pharmaceutical Operations President David Stout told investors in New York City Feb. 13

Medicare Rx Hinges On Senate Finance Cmte.; White House Delays Details

The prospects for a Medicare drug benefit in 2003 are likely to hinge on the ability of the Senate Finance Committee to find a bipartisan consensus over the next several months

Related Content

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel